RedHill Biopharma has initiated the patient screening process for a Phase III trial in the U.S. designed to evaluate the safety and efficacy of RHB-105 as a first-line treatment for confirmed Helicobacter pylori (H. pylori) bacterial infection. Initiation of the RHB-105 Phase III study follows the necessary approvals including FDA acceptance of the Company’s Investigational New Drug (IND) application and Institutional Review Board (IRB) approval. RHB-105 is a new and proprietary fixed-dos...